Elimination of asymmetric dimethylarginine by the kidney and the liver: A link to the development of multiple organ failure?

Journal of Nutrition

Volumn 134, Issue 10 SUPPL., 2004, Pages

  Nijveldt, Robert J ^a   Siroen, Michiel P C ^a   Teerlink, Tom ^a   Van Leeuwen, Paul A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Kidney; Liver; Multiple organ failure; Nitric oxide

Indexed keywords

DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE METHYLTRANSFERASE;

AMINO ACID METABOLISM; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CRITICAL ILLNESS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY METABOLISM; LIVER FAILURE; LIVER METABOLISM; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; RISK FACTOR;

EID: 4744374104     PISSN: 00223166     EISSN: None     Source Type: Journal    
DOI: 10.1093/jn/134.10.2848s     Document Type: Conference Paper

References (39)

1. Vallance P., Leone, A., Calver, A., Collier, J. & Moncada, S. (1992) Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20 (suppl. 12): S60-S62.
2. Böger, R. H., Böde-Boger, S. M., Szuba, A., Tsao, P. S., Chan, J. R., Tangphao, O., Blaschke, T. F. & Cooke, J. P. (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98: 1842-1847.
3. Böger, R. H., Böde-Boger, S. M., Thiele, W., Junker, W., Alexander, K. & Frolich, J. C. (1997) Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95: 2068-2074.
4. Miyazaki, H., Matsuoka, H., Cooke, J. P., Usui, M., Ueda, S., Okuda, S. & Imaizumi, T. (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99: 1141-1146.
5. Valkonen, V. P., Paiva, H., Salonen, J. T., Lakka, T. A., Lehtimaki, T., Laakso J. & Laaksonen, R. (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128.
6. Böger, R. H. (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res. 59: 824-833.
7. Najbauer, J., Johnson, B. A., Young, A. L. & Aswad, D. W. (1993) Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyltransferase(s) modifying arginine in numerous proteins. J. Biol. Chem. 268: 10501-10509.
8. + carrier hCAT-2B. Nitric Oxide 1: 65-73.
9. Vallance, P., Leone, A., Calver, A., Collier, J. & Moncada, S. (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575.
10. G-dimethylarginine dimethylaminohydrolase. Eur. J. Biochem. 258: 863-868.
11. G-dimethylarginine dimethylaminohydrolase, from rat kidney. J. Biol. Chem. 264: 10205-10209.
12. Ogawa, T., Kimoto, M. & Sasaoka, K. (1990) Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2. J. Biol. Chem. 265: 20938-20945.
13. Tojo, A., Welch, W. J., Bremer, V., Kimoto, M., Kimura, K., Omata, M., Ogawa, T., Vallance, P. & Wilcox, C. S. (1997) Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 52: 1593-1601.
14. G-dimethylarginine dimethylaminohydrolase in the nitric oxide-generating systems of rats using monoclonal antibody. Arch. Biochem. Biophys. 300: 657-662.
15. G-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J. Biochem. 117: 237-238.
16. Dayoub, H., Achan, V., Adimoolam, S., Jacobi, J., Stuehlinger, M. C., Wang, B. Y., Tsao, P. S., Kimoto, M., Vallance, P. et al. (2003) Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis. Genetic and physiological evidence. Circulation 108: 3042-3047.
17. Kielstein, J. T., Böger, R. H., Bode-Böger, S. M., Schaffer, J., Barbey, M., Koch, K. M. & Frolich, J. C. (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol. 10: 594-600.
18. Zoccali, C., Bode-Böger, S., Mallamaci, F., Benedetto, F., Tripepi, G., Malatino, L., Cataliotti, A., Bellanuova, I., Fermo, I., Frolich, J. & Böger, R. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117.
19. Zoccali, C., Mallamaci, F., Maas, R., Benedetto, F. A., Tripepi, G., Malatino, L. S., Cataliotti, A., Bellanuova, I. & Boger, R. (2002) Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 62: 339-345.
20. Fleck, C., Janz, A., Schweitzer, F., Karge, E., Schwertfeger, M. & Stein, G. (2001) Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int. Suppl. 78: S14-S18.
21. Yudkoff, M., Nissim, I., Pereira, G. & Segal, S. (1984) Urinary excretion of dimethylarginines in premature infants. Biochem. Med. 32: 242-251.
22. G-dimethylarginine in renal insufficiency. Pflugers Arch. 439: 524-531.
23. Nijveldt, R. J., van Leeuwen, P. A., van Guldener, C., Stehouwer, C. D., Rauwerda, J. A. & Teerlink, T. (2002) Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol. Dial. Transplant. 17: 1999-2002.
24. MacAllister, R. J., Parry, H., Kimoto, M., Ogawa, T., Russell, R. J., Hodson, H., Whitley, G. S. & Vallance, P. (1996) Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br. J. Pharmacol. 119: 1533-1540.
25. Murray-Rust, J., Leiper, J., McAlister, M., Phelan, J., Tilley, S., Santa, M. J., Vallance, P. & McDonald, N. (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat. Struct. Biol. 8: 679-683.
26. Ito, A., Tsao, P. S., Adimoolam, S., Kimoto, M., Ogawa, T. & Cooke, J. P. (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase Circulation 99: 3092-3095.
27. Nijveldt, R. J., Teerlink, T., van Guldener, C., Prins, H. A., van Lambalgen, A. A., Stehouwer, C. D., Rauwerda, J. A. & van Leeuwen, P. A. (2003) Handling of asymmetrical dimethylarginine (ADMA) and symmetrical dimethylarginine (SDMA) by the rat kidney under basal conditions and during endotoxemia. Nephrol. Dial. Transplant. 18: 2542-2550.
28. Carnegie, P. R., Fellows, F. C. & Symington, G. R. (1977) Urinary excretion of methylarginine in human disease. Metabolism 26: 531-537.
29. Nijveldt, R. J., Teerlink, T., Siroen, M. P., van Lambalgen, A. A., Rauwerda, J. A. & van Leeuwen, P. A. (2003) The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin. Nutr. 22: 17-22.
30. Tsikas, D., Rode, I., Becker, T., Nashan, B., Klempnauer, J. & Frolich, J. C. (2003) Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2α in end-stage liver disease. Hepatology 38: 1063-1064.
31. Nijveldt, R. J., Teerlink, T., van der Hoven, B., Siroen, M. P., Kuik, D. J., Rauwerda, J. A. & van Leeuwen, P. A. (2003) Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin. Nutr. 22: 23-30.
32. Baue, A. E., Durham, R. & Faist, E. (1998) Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 10: 79-89.
33. Harbrecht, B. G., Doyle, H. R., Clancy, K. D., Townsend, R. N., Billiar, T. R. & Peitzman, A. B. (2001) The impact of liver dysfunction on outcome in patients with multiple injuries. Am. Surg. 67: 122-126.
34. Lopez, A., Lorente, J. A., Steingrub, J., Bakker, J., McLuckie, A., Willatts, S., Brockway, M., Anzueto, A., Holzapfel, L. et al. (2004) Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32: 21-30.
35. Nijveldt, R. J., Teerlink, T. & van Leeuwen, P. A. (2003) The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis. Clin. Nutr. 22: 99-104.
36. Osanai, T., Saitoh, M., Sasaki, S., Tomita, H., Matsunaga, T. & Okumura, K. (2003) Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension 42: 985-990.
37. Laussmann, T., Janosi, R. A., Fingas, C. D., Schlieper, G. R., Schlack, W., Schrader, J. & Decking, U. K. (2002) Myocardial proteome analysis reveals reduced NOS inhibition and enhanced glycolytic capacity in areas of low local blood flow. FASEB J. 16: 628-630.
38. Hori, T., Matsubara, T., Ishibashi, T., Ozaki, K., Tsuchida, K., Mezaki, T., Tanaka, T., Nasuno, A., Kubota, K. et al. (2003) Significance of asymmetric dimethylarginine (ADMA) concentrations during coronary circulation in patients with vasospastic angina, Circ. J. 67: 305-311.
39. Achan, V., Broadhead, M., Malaki, M., Whitley, G., Leiper, J., MacAllister, R. & Vallance, P. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 23: 1455-1459.